Proresolving and Tissue-Protective Actions of Annexin A1–Based Cleavage-Resistant Peptides Are Mediated by Formyl Peptide Receptor 2/Lipoxin A4 Receptor
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Endogenous mechanisms regulating the host response during inflammation resolution are critical in ensuring disposal of noxious stimuli and return to homeostasis. In this article, we engineered novel Annexin A1 (AnxA1)–based peptides, AnxA12–50, that displayed specific binding to the AnxA1 receptor (formyl peptide receptor 2/Lipoxin A4 receptor [FPR2/ALX]; IC50 ∼4 nM). Intravenous administration of AnxA12–50 markedly reduced (>60%) leukocyte adhesion to postcapillary venules in wild type and Fpr1−/−, but not Fpr2/Alx−/−, mice. Generation of a metabolically stable form of this peptide (CR-AnxA12–50), engineered by substituting a cleavage site shared by human proteinase 3 and neutrophil elastase, yielded an agonist that was resistant to neutrophil-mediated cleavage and displayed enhanced proresolving actions: accelerated resolution of self-limited inflammation and enhanced macrophage efferocytosis after sterile injury, when compared with AnxA12–50. These actions were retained with human primary leukocytes where CR-AnxA12–50 decreased neutrophil–endothelial interactions (∼25–45%), and stimulated neutrophil apoptosis and macrophage efferocytosis (∼45%). In murine cardiac ischemia/reperfusion injury, CR-AnxA12–50 elicited tissue-protective actions reducing infarct size (∼60%) and incidence of 24-h death. These results identify AnxA12–50 and CR-AnxA12–50 as FPR2/ALX agonists that harness the proresolving actions of AnxA1, and thus may represent therapeutic tools for treatment of inflammatory conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552 · cited 6×
“In view of the pivotal roles that apoptosis (38) and efferocytosis (2) play in inflammatory resolution, these experiments were important to define the correct pharmacology of these novel AnxA1-derivatives, allowing us to identify them as proresolving peptides.”
BackgroundInfluentialNathan, C., & Ding, A. (2010) · Cell · doi:10.1016/j.cell.2010.02.029 · Cited by 2,183
Resolution of in flammation: state of the art, definitions and terms
Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A. J., Perretti, M., Rossi, A. G., & Wallace, J. L. (2007) · The FASEB Journal · doi:10.1096/fj.06-7227rev · Cited by 1,045 · cited 1×
“A cute inflammation represents a protective process mounted by the host in response to tissue damage and/or pathogenic infection (1, 2).”
BackgroundSelf-citationAnnexin A1 and glucocorticoids as effectors of the resolution of inflammation
Perretti, M., & D'Acquisto, F. (2009) · Nature Reviews Immunology · doi:10.1038/nri2470 · Cited by 915 · cited 1×
“Full-length AnxA1 exerts potent leukocyte-directed actions in vivo (28); therefore, we investigated whether AnxA12–50 also displayed anti-inflammatory properties.”
BackgroundSelf-citationMolecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins
Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., Hong, S., & Serhan, C. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4345 · Cited by 699
Bozinovski, S., Uddin, M., Vlahos, R., Thompson, M., McQualter, J. L., Merritt, A.-S., Wark, P. A. B., Hutchinson, A., Irving, L. B., Levy, B. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109382109 · Cited by 163 · cited 2×
“Notably, it has recently been demonstrated in that serum amyloid A, another FPR2/ALX may blunt the anti-inflammatory actions of LXA4, which, in turn, may mediate glucocorticoid refractory lung inflammation in patients with chronic obstructive pulmonary disease (39).”
BackgroundDufton, N., Natividad, J., Verdu, E. F., & Wallace, J. L. (2012) · Scientific Reports · doi:10.1038/srep00499 · Cited by 95 · cited 1×
“Clearance of apoptotic cells and debris by macrophages is a critical process occurring during resolution that is regulated by a number of endogenous resolution agonists including Resolvin D1 (14), hydrogen sulfide (37), and indeed, AnxA1 (7).”
BackgroundAyoub, S. S., Yazid, S., & Flower, R. J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.166 · Cited by 48
Cited by
Sugimoto, M. A., Vago, J. P., Teixeira, M. M., & Sousa, L. P. (2016) · Journal of Immunology Research · doi:10.1155/2016/8239258 · Cited by 414
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
The resolution of inflammation: Principles and challenges
Headland, S. E., & Norling, L. V. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.014 · Cited by 410
Wound repair: role of immune–epithelial interactions
Leoni, G., Neumann, P.-A., Sumagin, R., Denning, T. L., & Nusrat, A. (2015) · Mucosal Immunology · doi:10.1038/mi.2015.63 · Cited by 302
Cooray, S. N., Gobbetti, T., Montero-Melendez, T., McArthur, S., Thompson, D., Clark, A. J. L., Flower, R. J., & Perretti, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308253110 · Cited by 299
Self-citation
Metadata
- Authors
- Dalli, J., Consalvo, A. P., Ray, V., Di Filippo, C., D’Amico, M., Mehta, N., & Perretti, M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06
- Volume
- 190
- Issue
- 12
- Pages
- 6478-6487
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2124502562
- Cited by
- 103
- References
- 8
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.